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Volume 53, Number 1 Abstracts 259The State of Endovenous Ablation for Venous Insufficiency in Florida
M. S. Hong, K. Butler, T. D. Fischer, and P. R. Nelson, University of
Florida, Gainesville, Fla
Background: Endovenous ablation has recently been adopted for
treatment of lower extremity venous insufficiency. We sought to define the
current trends in the use of endovenous procedures and the impact on the
associated costs in the state of Florida (Fig).
Methods: The Agency for Healthcare Administration database,
which contains 100% of encounters from ambulatory centers in Florida,
was queried for endovenous laser or radiofrequency ablation procedures,
using Current Procedural Technology codes 36478 and 36475, respec-
tively, for the study period of Q1 of 2005 to Q3 of 2008. International
Classification of Diseases-9 diagnostic codes were used to identify sever-
ity of the venous disease. The main measures included type of ablation,
provider specialty, and total charges. A comparison of practice patterns
and associated charges were performed for the two main provider groups,
namely general/vascular surgeons (GS/VS) and diagnostic/interven-
tional radiologists (DR/IR).
Results: Our query consisted of 4,143 encounters during the study
period. The mean age was 54  13 years, and 73% were women.
Compared with the Florida population, white and white-Hispanic race
was over-represented (91.4% vs Florida 81%), and black race was under-
represented (4.3% vs Florida 16%). The most common complaint was
edema, pain, or swelling (45.5%), followed by varicose veins with inflam-
mation (17.8%), unspecified venous insufficiency (12.6%), asymptomatic
varicose veins (11.9%), and phlebitis/thrombophlebitis (10.2%). Laser
ablation outnumbered radiofrequency ablation each year (mean 697 vs
416 per year, respectively). Vascular and general surgeons comprised the
vast majority of providers, consisting of 48.7% and 40.9% of encounters,
respectively. Other providers of note include cardiothoracic surgeons
(1.2%) and DR/IR (3.8%). In total, 21 specialties were represented.
GS/VS providers performed secondary ablations in 32.5% encounters,
and stab phlebectomies in 18.2%. In contrast, DR/IR performed second-
ary ablations in only 3.8%, and stab phlebectomy in 5.1%. Total charges
overall were $11,644  $6,682; $11,696  6,594 for GS/VS and
$6,392  4,820 for DR/IR. Most of this difference was due to charges
related to the operating room ($7,858 GS/VS and $3,944 DR/IR),
likely reflecting differences in practice patterns.
Table I. Ultrasound result on 59 completed legs
Venous
status
3 years above
knee n (%)
Group surgery (n 
26)
1 17 (65.4)
2 2 (7.7)
3 7 (26.9)
Group foam (n  33) 1 16 (48.5)
2 6 (18.2)
3 11 (33)
Mann-Whitney U test P P  .298Venous status: 1, occluded; 2, competent; 3, reflux.Conclusions: Endovenous ablation offers a minimally invasive op-
tion for treatment of venous insufficiency. Although providers span a
wide range of specialties, the majority of endovenous ablations per-
formed in ambulatory centers are performed by general or vascular
surgeons. GS/VS performed substantially more secondary procedures
compared with DR/IR, resulting in higher total charges. More studies
are required to determine whether this disparity in practice patterns result
in different outcomes.
Randomized Controlled Trial of Ultrasound Guided Foam Sclerother-
apy Combined with Sapheno-Femoral Ligation Compared to Surgical
Treatment of Varicose Veins: Five-year Results
E. Kalodiki,a M. Azzam,b C. R. Lattimer,a E. Shawish,b N. Zambas,b and G.
Geroulakosa, The Ealing Hospital and Imperial College London, London,
United Kingdom,a and the Ealing Hospital, Middlesex, United Kingdom.b
Background: Up to 5-year results of a prospective randomized con-
trolled trial comparing foam sclerotherapy and surgery to standard surgery,
in patients with primary varicose veins.
Methods: Seventy-three patients (82 legs) underwent sapheno-femo-
ral ligation, stripping, and multiple phlebectomies under general anesthesia
(n  39; M:F, 16:23; mean age, 47 years [range, 23-76 years]; group S) or
sapheno-femoral ligation under local anesthesia and concurrent sclerother-
apy (n 43;M:F, 11:32; mean age, 49 years [range, 26-42 years]; group F).
Assessments included CEAP classification, ultrasound, Venous Clinical Se-
verity Score (VCSS), Aberdeen Varicose Vein Questionnaire (AVVQ), and
Short Form 36 (SF36) scores.
Results: CEAP was similar between groups, C2-6. On the 59 legs with
completed ultrasound, reflux at 3 to 5 years is presented (Table I).
In group S, 40% of legs required 25 additional foam sessions with a
mean volume of 11 mL and a total volume of 154 mL. In group F, 47.5% of
legs required 33 additional sessions with a mean volume of 9 mL and a total
volume of 207 mL. Preoperatively the VCSS score was equivalent between
the two groups (median-range-Interquartile Range [IQR]; group S: 5,
3-12, 3 and group F: 4.5, 2-15, 2; P  .359 Mann-Whitney U test).
However, after treatment there was improvement within both groups (me-
dian-range-IQR for group S: 1, 0-9, 5; P .001; for group F: 1, 0-9, 2; P
.0005Wilcoxon). Changes in VCSS before and at 3 years (P .504) and the
absolute VCSS scores (P  .313) were similar between both groups. The
Venous Disease Severity Score (VSDS) score improved in both groups due
to treatment (Table II).
The AVVQ score also improved within both groups (median-
interquartile range preoperatively vs 3 years [S: 16.32-4.7 vs 8.94-11.51;
P  .003; F: 12.28-10.37 vs 4.97-6.19; P  .0005 Wilcoxon). The
improvement on the AVVQ score before and after treatment was similar
5 years above
knee n (%)
3 years below
knee n (%)
5 years below
knee n (%)
14 (53.8) 6 (23.1) 10 (38.5)
3 (11.5) 6 (23.1) 7 (26.9)
9 (34.6) 14 (53.8) 9 (34.6)
19 (57.6) 15 (45.5) 8 (24.2)
1 (3.0) 4 (12.1) 11 (33.3)
13 (39.4) 14 (42.4) 14 (42.4)
P  .194 P  1.000 P  .341
Table II. Venous Clinical Severity Score up to 5 years
between groups on 70 patients
Group surgery
median
(IQR)
Group foam
median
(IQR)
Mann-Whitney
U Test
Pretreatment 1.0 (1.3) 1.0 (1.0) P  .518
3 years 0.5 (1.0) 1.0 (1.0) P  .780
5 years 1.0 (1.0) 0.25 (1.0) P  .388
Friedman P  .0005 P  .0005
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scoring over 3 years improved in group S (P  .04). However, there was
no change in the physical scores in both groups (S: P .361; F: P .889)
or the mental score in group F (P  .285). Furthermore, there was no
difference in the changes on the physical and mental score between the
treatment groups due to treatment (physical P  .724, mental P  .354,
Mann-Whitney U test).
Conclusions: At 3 to 5 years follow up, the treatment was equally
effective between the two groups, as demonstrated with VSDS, VCCS, and
AVVQ score improvements. The additional foam sessions were also similar.
Since surgery may not provide a definitive solution, foam sclerotherapy
could be offered like a dental care treatment model (ie, “treat as and when
the problem appears”).
A New Approach to the Genetics of Varicose Veins: A Genome-wide
Association Study
A. M. van Rij, J. Krysa, and G. T. Jones, The University of Otago, Dunedin,
New Zealand
Background: The exact nature of the genetic basis of varicose veins
remains unclear. A number of genetic associations have been described.
These have, however, all been relatively small, limited-candidate gene
studies, none of which have been validated. The aim of this study was to
consider these current reported genetic associations with varicose veins
and to carry out a case control analysis to validate them, using the
approach of a more comprehensive nonbiased genome-wide association
study (GWAS).
Methods: An indirect, in silico, GWAS of varicose veins was under-
taken. This was based on our abdominal aortic aneurysmGWAS in which the
frequency of varicose veins was similar in cases and controls. Genetic
polymorphisms associations with venous disease to date were identified
through a literature search. All known single nucleotide polymorphisms,
with5% allele frequency in the genes previously implicated, were analyzed.
Genotyping was carried out using Affymetrix genome-wide human single
nucleotide polymorphisms array 6.0.
Results:Three hundred forty-nine patients with varicose veins and 857
controls were included. Genes which have been implicated in venous disease
so far include FOXC2,HFE C282Y, factor XIII V34L, estrogen receptor B,
TNF-A, MTHFR, and thrombomodulin. None of the single-nucleotide
polymorphisms in these genes have shown to have significant association in
this study. However, there were a number of other single-nucleotide poly-
morphisms that were found to be associated with varicose veins. Some of
these are quite novel and previously not linked to venous disease. These are
being further validated in another larger and more strictly phenotyped
cohort.
Conclusions: This is the first GWAS applied to varicose veins. The
previous candidate genes implicated in common venous disease have not
been confirmed. A GWAS approach has been shown to be useful in valida-
tion and discovery of novel genes in venous disease. Further larger cohorts
are required to confirm these.
Thrombolytic Therapy with Tissue Plasminogen Activator: Why Pro-
longed Continuous Infusion is not the Best Approach
R. Chang, J. N. Lozier, and M. K. Horne III, The National Institutes of
Health, Rockville, Md
Background:Continuous infusion has been assumed to be the optimal
way of administering every thrombolytic agent approved for clinical use.
However, this simplistic approach fails to take advantage of differences in
properties of thrombolytic agents that could be exploited to increase efficacy
as well as safety. In particular, continuous infusion is not necessary when
using thrombolytic agents with strong fibrin binding and is not the optimal
way of administering recombinant tissue plasminogen activator (r-tPA or
alteplase). Once given by intraclot injection, alteplase binds to fibrin clot,
and once bound to clot, its activity as a plasminogen activator increases
several hundred-fold, also known as fibrin selectivity. Once the clot has been
laced with tPA, prolonged fibrinolysis ensues, obviating the need for pro-
longed infusions.
Methods: Forty-five patients with subclavian, jugular, or central ve-
nous thrombosis (SJ-CVT) and 56 patients with acute deep vein thrombosis
of the lower extremity (DVT-LE) were treated with once daily intraclot
pulse spray injection of tPA without prolonged infusions of tPA, but with
full systemic anticoagulation. Initial protocols used high doses of tPA (20-40
mg/day for SJ-CVT, and up to 50 mg/day for DVT-LE) but were reduced
five- to ten-fold to amaximumof 4mg/day tPA for SJ-CVT and amaximum
of 10 mg/day tPA for DVT-LE after pharmacokinetic studies indicated the
higher doses greatly exceeded the amount of tPA that could bind to acute
fibrin clot.
Results: Venous patency was restored in 34 of 45 (76%) SJ-CVT
patients after an average of 2.1 days/treatments and 51 of 56 (91%) of acute
DVT-LE patients after an average of 2.7 days/treatments. There was no lossof efficacy with decrease in dose of tPA. No major bleeding complications
requiring transfusion were found at either dosing schedule.
Conclusions: Elimination of prolonged continuous infusion from
thrombolytic regimens using tPA has two advantages. When many venous
divisions are thrombosed, the catheter can be moved from one division to
the next to load each segment of clot with tPA quickly, instead of having to
leave the catheter in one division for prolonged infusion. This allows
thrombolysis of many divisions in almost parallel fashion instead of the serial
fashion required with conventional thrombolytic therapy. The second ad-
vantage is safety, because with termination of intraclot injection, any tPA
that reached the systemic circulation during injection is cleared rapidly due
to its short half-life (T.5 5min) shortening the duration of circulating tPA,
whereas with conventional thrombolytic therapy, elevated systemic tPA
levels and suppressed plasminogen activator inhibitor-1 levels are likely to
persist as long as the prolonged infusion continues.
Postoperative Deep Vein Thrombosis in Total Knee or Hip Replace-
ment Operation is Associated with Preoperative Increased Calf Muscle
Deoxygenation
T. Yamaki, A. Hamahata, D. Fujisawa, H. Konoeda, K. Kubo, M. Nozaki,
and H. Sakurai, The Tokyo Women’s Medical University, Tokyo, Japan
Background: To assess whether preoperative calf muscle deoxygen-
ated hemoglobin (HHb) level during light-intensity exercise is useful for
identifying patients at risk of developing postoperative deep vein thrombosis
(DVT).
Methods:Sixty-three patients receiving either total knee or total hip
replacement operation were enrolled. Preoperative screening using com-
pression ultrasound of the bilateral lower extremities was performed if study
patients already had deep vein thrombosis. The mean flow velocity of the
popliteal vein (POPV) was assessed. Moreover, prevalence of venous reflux
in the POPV was evaluated preoperatively. Near-infrared spectroscopy was
used to measure calf muscle HHb levels. Calf venous blood filling index
(HHbFI) was calculated on standing, then the calf venous ejection index
(HHbEI) was obtained after one tiptoe movement and the venous retention
index (HHbRI) after ten tiptoe movements. All patients received fondapa-
rinux for postoperative thromboprophylaxis.
Results: There were no preoperative DVT. Of 63 patients evaluated,
postoperative compression ultrasound confirmed DVT in 13 (20.6%) pa-
tients. There were no significant differences in mean age, body mass index,
and gender distributions between patients with postoperative DVT and
those without. There was no significant difference in the mean flow velocity
in the POPV between patients with postoperative DVT and these without (P
 .062). Reflux in the POPV was found in three patients with postoperative
DVT and 12 without postoperative DVT, and there was no significant
difference between the groups (P  .945). The preoperative near-infrared
spectroscopy-derived HHbRI was significantly increased in patients who
developed deep vein thrombosis in comparison with those who did not
(7.78  8.65, 1.83  2.30; P  .006, respectively). There were no
significant differences in the values of HHbFI and HHbEI between the
study groups.
Conclusions: These results suggest that HHbRI, as measured by
near-infrared spectroscopy, may be a promising parameter for identifying
patients at risk of developing postoperative DVT despite pharmacologic
deep vein thrombosis prophylaxis. These findings might be very helpful for
physician in detecting patients who require more extensive thromboprophy-
laxis.
Patient Characteristics, Referral Patterns and Associated Risk Factors
in Patients Referred to an Outpatient Vascular Laboratory to Rule out
Deep Venous Thrombosis
K. Gibson,a N. L. Polissar,b and M. B. Neradilek,b Lake Washington
Vascular Surgeons, Bellevue, Wash,a and The Mountain-Whisper-Light
Statistics, Seattle, Wash.b
Background: Previous studies utilizing national or regional data dem-
onstrated that a significant proportion of deep vein thrombosis (DVT) is
diagnosed in the outpatient setting. Little is known, however, about patient
characteristics, referral patterns, and percentage of positive DVT in patients
referred to outpatient vascular laboratories. The study objective was to
examine demographics, risk factors, presenting symptoms, and referring
physician specialties in patients referred to outpatient vascular laboratories
(OVL) and to delineate clot extent in patients diagnosed with DVT.
Methods:Data was retrospectively collected from an OVL database of
1506 patients referred to rule out DVT over a 13-month period. Data
collected included patient age, gender, risk factors, presenting symptom(s),
and referring physician specialty. In patients with positive findings, the DVT
were categorized (acute or chronic), and extent of DVT was classified on a
scale of 1 to 4 (4  gastronemius vein, 3  tibial vein, 2  femoral and/or
popliteal vein, and 1  common femoral and/or more proximal veins).
Logistic regression was used to quantify association of risk factors with the
presence of acute DVT.
